Tumor Immune Microenvironment in Cancer Progression and Cancer Therapy PDF
Preview Tumor Immune Microenvironment in Cancer Progression and Cancer Therapy
Advances in Experimental Medicine and Biology 1036 Pawel Kalinski Editor Tumor Immune Microenvironment in Cancer Progression and Cancer Therapy Advances in Experimental Medicine and Biology Volume 1036 Editorial Board: IRUN R. COHEN, The Weizmann Institute of Science, Rehovot, Israel ABEL LAJTHA, N.S.Kline Institute for Psychiatric Research, Orangeburg, NY, USA JOHN D. LAMBRIS, University of Pennsylvania, Philadelphia, PA, USA RODOLFO PAOLETTI, University of Milan, Milan, Italy NIMA REZAEI, Tehran University of Medical Sciences, Children’s Medical Center Hospital, Tehran, Iran More information about this series at http://www.springer.com/series/5584 Pawel Kalinski Editor Tumor Immune Microenvironment in Cancer Progression and Cancer Therapy Editor Pawel Kalinski Department of Medicine and Center for Immunotherapy Roswell Park Cancer Institute Buffalo, NY, USA ISSN 0065-2598 ISSN 2214-8019 (electronic) Advances in Experimental Medicine and Biology ISBN 978-3-319-67575-6 ISBN 978-3-319-67577-0 (eBook) https://doi.org/10.1007/978-3-319-67577-0 Library of Congress Control Number: 2017960767 © Springer International Publishing AG 2017 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Printed on acid-free paper This Springer imprint is published by Springer Nature The registered company is Springer International Publishing AG The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland Preface Tumor microenvironment (TME) and the patterns of local interactions between malignant cells, tumor stroma, and inflammatory infiltrate have been extensively demonstrated to be essential for the survival of cancer cells, their proliferation and invasion into surrounding tissues, and formation of distant metastasis, as well as their resistance to treatments. More recent works demonstrate that the immune component of the TME (iTME) and the interactions between different types of immune cells, tumor- associated fibroblasts, and cancer cells are critical for the success, and fre- quent failure, of the spontaneously arising anticancer immunity and for the effectiveness of different forms of immunotherapy. Most strikingly, recent reports documented the critical role of the immune system and iTME in the effectiveness of radio-and chemotherapy, the pillars of cancer treatment that were traditionally considered as immunosuppressive, rather than immunostimulatory. This book Tumor Immune Microenvironment in Cancer Progression and Cancer Therapy compiles 14 chapters discussing the roles of different iTME components (cells, proteins, and nonprotein mediators) in tumor progression, metastatic process, and different forms of cancer treatment, as well as newly arising opportunities for their modulation to enhance the overall therapeutic benefit of the comprehensive cancer care. After decades of controversies regarding the role of immune system in controlling cancer growth, fueled by frequent dissociation between the levels of systemic immunity against tumor-related antigens (observed in the blood) and cancer progression, recent clinical and animal studies have demonstrated that the immune component of the TME is the key predictor of cancer pro- gression and treatment outcomes. A striking example is the effectiveness of checkpoint inhibitors, where the clinical responses and long-lasting therapeu- tic benefit of individual patients, even patients with advanced cancer, can be predicted by the levels of infiltration with cytotoxic T cells (CTLs) within the TME. However, the current methods of evaluation of different iTME compo- nents, and evaluating their intrinsic plasticity and context-dependent roles at different stages of antitumor responses are not absolutely reliable. This war- rants the development of new methods of TME analysis to optimally define predictive markers and targets for cancer therapy. v vi Preface I wholeheartedly thank all the authors, leaders in their respective fields, who took time from their labs and other duties to share with you their insights on different aspects of iTME during the progression of cancer and its treatment. I hope that you will find this book interesting, thought provoking, and helpful in your research. Buffalo, NY, USA Pawel Kalinski Contents 1 Tumor Immuno-Environment in Cancer Progression and Therapy ................................................................................... 1 Pawel Kalinski and James E. Talmadge 2 Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell- Inflamed Tumor Microenvironment ......................................................................... 19 Thomas F. Gajewski, Leticia Corrales, Jason Williams, Brendan Horton, Ayelet Sivan, and Stefani Spranger 3 Regulation of CTL Infiltration Within the Tumor Microenvironment ......................................................................... 33 Sarah E. Church and Jérôme Galon 4 The Role of Tumor Microenvironment in Cancer Immunotherapy ............................................................................. 51 Timothy Frankel, Mirna Perusina Lanfranca, and Weiping Zou 5 Immunogenic and Non- immunogenic Cell Death in the Tumor Microenvironment ................................................. 65 Jonathan M. Pitt, Guido Kroemer, and Laurence Zitvogel 6 Exosomes in Cancer: Another Mechanism of Tumor-Induced Immune Suppression ........................................ 81 Theresa L. Whiteside 7 Chemo-Immunotherapy: Role of Indoleamine 2,3-Dioxygenase in Defining Immunogenic Versus Tolerogenic Cell Death in the Tumor Microenvironment .......... 91 Theodore S. Johnson, Tracy Mcgaha, and David H. Munn 8 Targeting Myeloid-Derived Suppressor Cells in Cancer ........... 105 Waseem Anani and Michael R. Shurin vii viii Contents 9 T ryptophan Catabolism and Cancer Immunotherapy Targeting IDO Mediated Immune Suppression ......................... 129 Adaobi Amobi, Feng Qian, Amit A. Lugade, and Kunle Odunsi 10 L ipid Inflammatory Mediators in Cancer Progression and Therapy ................................................................................... 145 Saraswoti Khadge, John Graham Sharp, Timothy R. McGuire, Geoffrey M. Thiele, and James E. Talmadge 11 O ncolytic Virotherapy and the Tumor Microenvironment ....... 157 Sara E. Berkey, Steve H. Thorne, and David L. Bartlett 12 T he Impact of Housing Temperature-Induced Chronic Stress on Preclinical Mouse Tumor Models and Therapeutic Responses: An Important Role for the Nervous System ............................................................................. 173 Bonnie L. Hylander, Jason W.-L. Eng, and Elizabeth A. Repasky 13 Immunotherapeutic Targeting of Tumor-Associated Blood Vessels .................................................................................. 191 Kellsye L. Fabian and Walter J. Storkus 14 A daptive Resistance to Cancer Immunotherapy ....................... 213 A.J. Robert McGray and Jonathan Bramson 15 Imaging the Tumor Microenvironment ....................................... 229 Marie-Caline Z. Abadjian, W. Barry Edwards, and Carolyn J. Anderson Index ....................................................................................................... 259 Contributors Marie-Caline Z. Abadjian Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA Adaobi Amobi Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY, USA Center for Immunotherapy, Roswell Park Cancer Institute, Buffalo, NY, USA Waseem Anani, M.D. Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA Carolyn J. Anderson Department of Pharmacology & Chemical Biology, University of Pittsburgh, Pittsburgh, PA, USA Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, USA W. Barry Edwards Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, USA David L. Bartlett Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA Sara E. Berkey Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA Jonathan Bramson, B.Sc., Ph.D. Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada Sarah E. Church Laboratory of Integrative Cancer Immunology, INSERM, UMRS1138, Paris, France Université Paris Descartes, Paris, France Cordeliers Research Centre, Université Pierre et Marie Curie Paris 6, Paris, France Leticia Corrales University of Chicago, Chicago, IL, USA ix
The list of books you might like
